- Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage studyPemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Altimmune is going up against Eli Lilly and newcomer Baseline Therapeutics in this sp…BioSpace · 18m ago↗ source
- Claris collects $118M to take eye drop into pivotal testing next yearClaris Bio has a fresh CEO, new board chair and $118 million for two pivotal trials to see if its eye drop can succeed in a blinding disease with no pharmaceutical treatment options. It's a ...Endpoints · 1h ago↗ source
- An eye drug biotech banks $118M and stocks its executive suite<figure><div><img src="https://imgproxy.divecdn.com/cIH1PfJposjsKezbbrmwTwtzNlhqTiIaZ_OaEGGTHE8/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNjE5NzI0MTUxLmpwZ…